You can nudge adult cells partway toward a stem-like state, then stop short of full pluripotency. In a 2022 eLife report on maturation phase transient reprogramming (MPTR), researchers at the Babraham Institute and partner institutions studied dermal fibroblasts from three middle-aged donors (chronological ages thirty-eight, fifty-three, and fifty-three in the paper). That work sits among other emerging longevity technologies that are still mostly preclinical.
After 13 days of doxycycline-induced expression of Oct4, Sox2, Klf4, and c-Myc, followed by at least 4 weeks without doxycycline, the authors reported large shifts on laboratory aging clocks and some functional readouts, while cells moved back toward a fibroblast-like state. A later section covers a related phase 1 gene-therapy program; press reporting has stressed that FDA clearance to open a trial is not proof that a therapy works or is safe at scale.
Thirteen-day MPTR aligned with large clock shifts in cultured fibroblasts
MPTR means expressing reprogramming factors until the maturation phase, then switching them off so cells do not finish conversion into induced pluripotent stem cells. In their time-course, DNA methylation age on the multi-tissue Horvath clock fell during that middle phase, and they collected cells after 10, 13, 15, or 17 days of induction before the revert culture.
In this experiment, 13 days of successful MPTR produced the largest clock shifts they reported: median Horvath DNA methylation age fell by roughly thirty years versus matched controls, and a custom fibroblast transcriptome clock moved by a similar amount. Shorter and longer induction windows (10, 15, or 17 days in their design) showed smaller reductions in those analyses. The authors treat longer exposures cautiously because reversion may get harder and stress might offset gains. Those patterns describe one small in vitro dataset, not a general law for all cells or protocols.
Collagen-related signals and wound-assay speed after reprogramming stopped
The authors reported that collagen-related gene and protein signals shifted toward younger reference patterns after 13 days of MPTR. Collagen IV RNA changed more clearly than collagen I RNA; the paper notes that collagen I mRNA did not reach clear statistical significance despite an aging-related trend. Immunofluorescence still showed higher collagen I and IV protein in treated cells than in controls. They also used an in vitro wound-closure-style migration assay: fibroblasts from middle-aged donors moved more slowly than young reference cells, and MPTR raised median speed in some comparisons, though responses varied by donor and did not line up neatly with clock outputs.
These readouts can move together in a dish. They do not mean skin in a living person would heal faster or look younger after any similar intervention.
Identity return, telomeres, and what clocks do not prove
Intermediate cells could express early pluripotency surface markers and lose a fibroblast surface marker, yet RNA-seq and methylation principal-component trajectories returned toward fibroblast-like positions after factor withdrawal, and fibroblast marker expression resembled controls. The authors propose that retained low methylation at fibroblast-linked enhancers, together with persistent expression of some fibroblast genes, may help cells regain fibroblast identity after factors are withdrawn. That is a hypothesis, not a final mechanism.
Telomere length estimated from a DNA-methylation telomere clock did not increase after MPTR and could look slightly shorter in some comparisons, consistent with their observation that strong telomere lengthening in their system appeared only in later full-reprogramming stages.
Aging clocks compress many molecular readings into an age-like score. They are useful for comparing samples in research, but they are not the same as measuring real-world health in people. RNA-based clocks can also shift with batch and protocol; the paper flags batch effects for transcript predictors. Separately, everyday behaviors can shift epigenetic readouts without virus-delivered reprogramming factors.
Trial news extends the story but leaves outcomes open
In early 2026, journalists described FDA clearance to proceed with a first-in-human phase 1 study of ER-100, an AAV gene therapy that delivers OCT4, SOX2, and KLF4 under controlled expression for partial epigenetic reprogramming (Nature Biotechnology news brief). Life Biosciences announced the same IND clearance for optic neuropathies, including open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION). The ClinicalTrials.gov registration (NCT07290244) lists phase 1 outcomes centered on safety and tolerability (adverse events, dose-limiting toxicities, laboratory panels), immune responses (for example neutralizing antibodies to the vector and cellular responses to therapy-related peptides), and detailed vision assessments (visual acuity, visual fields, retinal structure and function on several tests). That design reflects early human risk monitoring, not demonstrated clinical benefit.
Dish-level fibroblast results and a sponsor-run eye trial answer different questions. Lifestyle and environmental factors still dominate modifiable aging risk in population data, separate from experimental gene-delivery programs.
What you can do with this information
Treat MPTR and related partial-reprogramming stories as active research. If a headline equates clock shifts with “turning back the clock” in a person, check whether the evidence is cultured cells, animals, or randomized human outcomes. Ask your clinician about any experimental therapy; do not self-experiment with reprogramming factors. Follow trial registrations and peer-reviewed results as they appear.
Sources and related information
eLife – Multi-omic rejuvenation of human cells by maturation phase transient reprogramming – 2022
This open-access research article supplies the MPTR protocol, donor ages, 13-day and revert culture windows, clock estimates, collagen and migration findings, identity-return analyses, and telomere-clock results summarized here. The PubMed Central mirror is PMC9023058.
Nature Biotechnology – FDA go-ahead to test cellular rejuvenation therapy in humans – 2026
This news brief reports FDA clearance to advance ER-100 into phase 1 testing as of its publication date; it is not a trial outcome report.
Life Biosciences – FDA clearance of IND for ER-100 in optic neuropathies – 2026
This company announcement states FDA clearance of the investigational new drug application for ER-100 in optic neuropathies, including open-angle glaucoma and NAION, matching the indication language used in this article.
ClinicalTrials.gov – Evaluating ER-100 for safety in glaucoma or NAION (NCT07290244) – 2025
This trial record documents the phase 1 sponsor, conditions (open-angle glaucoma and NAION), and primary outcome measures focused on safety, tolerability, laboratory monitoring, immune markers, and vision-related assessments during early follow-up.
